Reviewing Precigen (NASDAQ:PGEN) and Cleveland BioLabs (NASDAQ:CBLI)
Cleveland BioLabs (NASDAQ:CBLI) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Insider & Institutional Ownership
3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 74.1% of Precigen shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by company insiders. Comparatively, 44.0% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for Cleveland BioLabs and Precigen, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk & Volatility
Cleveland BioLabs has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Precigen has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cleveland BioLabs and Precigen’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cleveland BioLabs||$1.14 million||15.07||-$3.61 million||N/A||N/A|
|Precigen||$90.72 million||6.06||-$322.32 million||($0.88)||-3.68|
Cleveland BioLabs has higher earnings, but lower revenue than Precigen.
This table compares Cleveland BioLabs and Precigen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Precigen beats Cleveland BioLabs on 6 of the 9 factors compared between the two stocks.
About Cleveland BioLabs
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.